Search, analyze & compare

My selected companies

Adjust valuation method
WatchlistNameTickerP/EP/SP/BEV/EbitdaROEROICRSISMA200DCFVolumeClosing price
-
Enanta Pharmaceuticals IncENTA-1.722.751.19-1.65-59.64%-20.72%52.95$11.48$24.673,976$9.35

Detail of Enanta Pharmaceuticals Inc

 
CEO
Dr. Jay R. Luly
Employees
160
Industry
Biotechnology
Sector
Healthcare
Market cap
$198M

Company details

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.

Revenue
Revenue (Rev)
$67.64M
Enanta Pharmaceuticals Inc
ENTA • XNGS • US
$9.35
-2.99 (-24.23%)
Stock vs Industry average
  • Industry average

Negative values are hidden from the graph.
Trailing annual dividend rate
$0.00
Payout ratio
0.00%
EPS
-$5.48
Margin profit
-160.27%
52 week low
$8.8949
52 week high
$17.459999
50-day simple moving average
$0.00
200-day simple moving average
$11.48
Percent held by insiders
6.09%
Percent held by institutions
100.66%
Dividend yield
0.00%

Change of shares

Cash vs Debt

Insider Trading

Comparison of selected companies

 
%
Price change
ENTA -24.17%
eps change
ENTA 0.00%